Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 4/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992319 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4TDO2 | |
| SCHEMBL1989869 | 0.89 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4TDO2 | |
| SCHEMBL1989873 | 0.89 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4TDO2 | |
| SCHEMBL1991176 | 0.89 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4TDO2 | |
| SCHEMBL1991067 | 0.88 | BRD4 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CREBBP | |
| SCHEMBL1991068 | 0.88 | BRD4 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CREBBP | |
| SCHEMBL1994667 | 0.87 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CREBBP | |
| SCHEMBL1994668 | 0.87 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CREBBP | |
| SCHEMBL1989220 | 0.85 | PADI4 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1989217 | 0.85 | PADI4 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | claimed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | IDO2, IDO1, TPH2 | CHRNB2 522/4885CHRNB4 815/4885CHRNA3 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.